Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type - Journal of Cancer Therapy

JCT > Vol.10 No.12, December 2019

Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type ()

HTML XML

Download as PDF (Size: 743KB) PP. 908-914

DOI: 10.4236/jct.2019.1012077 600 Downloads 1,864 Views

Author(s)

Amen Hamdy Zaky^1*, Ahmed Refaat Abd Elzaher¹, Ola Nabih²

Affiliation(s)

¹Medical Oncology Department, South Egypt Cancer Institute, Assuit University, Assuit, Egypt.
²Clinical Oncology Department, Faculty of Medicine, Assuit University, Assuit, Egypt.

ABSTRACT

Background: This study was performed to evaluate the efficacy and safety of switch maintenance therapy with oral vinorelbine in advanced non-small cell lung cancer (NSCLC) with adenocarcinoma limited to epidermal growth factor receptor (EGFR) wild type. Materials and Methods: In this single randomized trial, patients with advanced stage (IIIB and IV) NSCLC with adenocarcinoma EGFR wild-type status, treated with 6 cycles of platinum based chemotherapy. Patients did not show progression after first-line chemotherapy were randomly assigned to receive switch maintenance with vinorelbine (80 mg/m², day 1, 8) (group I) or the best supportive care until disease progression (group II). Results: The median progression free survival (PFS) was 9.7 months for group I versus 5.7 months for group II with statistically significant difference between both groups [HR = 1.15; 95% CI 1.19 to 1.49; P value = 0.002], while the median overall survival (OS) was 13.2 months for group I versus 11.9 months for group II with no statistically significant differences between both groups [HR = 1.24; 95% CI 1.05 to 1.46; P value = 0. 3]. The patients who received oral vinorelbine had tolerable toxicity profile. Conclusion: Switch maintenance therapy with oral vinorelbine, though improve PFS, did not improve OS in patients with NSCLC with adenocarcinoma EGFR wild type.

KEYWORDS

Lung Cancer, Maintenance Chemotherapy, Vinorelbine, EGFR-Wild Type

Share and Cite:

Zaky, A. , Elzaher, A. and Nabih, O. (2019) Oral Vinorelbine as Switch Maintenance Therapy versus Best Supportive Care in Patients with Advanced Adenocarcinoma Non-Small Cell Lung Cancer EGFR Wild Type. Journal of Cancer Therapy, 10, 908-914. doi: 10.4236/jct.2019.1012077.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies